NCT03124368View on ClinicalTrials.gov

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

December 21, 2018

Study Completion Date

January 9, 2019

Conditions
C3 GlomerulonephritisDense Deposit DiseaseC3 GlomerulopathyImmune Complex Mediated Membranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis Types I, II, and III
Interventions
DRUG

Danicopan

Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).

Trial Locations (3)

Unknown

Clinical Trial Site, Melbourne

Clinical Trial Site, Antwerp

Clinical Trial Site, Leiden

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY